Stockreport

Gossamer Bio (GOSS) Is Up 17.7% After Seralutinib Gains Key FDA Support and Clinical Progress [Yahoo! Finance]

Gossamer Bio, Inc.  (GOSS) 
Last gossamer bio, inc. earnings: 3/24 07:00 am Check Earnings Report
PDF new FDA designations and positive clinical progress targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension linked with interstitial lung disease (PH- [Read more]